Mayne Pharma Group (ASX:MYX) has inaugurated its newly expanded manufacturing facility in Salisbury, South Australia.
The GMP, FDA, and TGA-accredited facility, spanning a 12-hectare site, is designed for large-scale production of solid oral and topical dosage forms, including tablets, capsules, powders, pellets, liquids, and creams.
Over the past two years, Mayne Pharma invested approximately $18 million to modernise and expand the plant, adding a high-speed encapsulation suite and other automation upgrades, enhancing production efficiency and quality.
The modernisation program received support through a $4.8 million Federal Government Modern Manufacturing Initiative grant, fully funded by June.
The upgraded facility now offers expanded manufacturing capacity and capabilities, including serialisation, enabling the company to support new product launches and exports.
In FY25, Mayne Pharma's International segment reported a 7% increase in revenue to $75.6 million, with gross profit rising 1% to $21.5 million and direct contribution reaching $7.4 million.
At the time of reporting, Mayne Pharma's share price was $3.19.